This special supplement to The Journal of Nuclear Medicine is a detailed tabulation of
literature on FDG PET in oncology (1993–June 2000), cardiology (1986–June 2000), and …

Positron emission tomography (PET) is the most powerful molecular imaging technique
currently available for clinical use. Because deranged tumour metabolism is a common …

This WHO classification covers tumors of soft tissue and bone including inherited tumor
syndromes. Each entity is extensively discussed with information on clinicopathological …

Purpose The objective of this study was to evaluate the impact of positron emission
tomography (PET) using fluorine-18–fluorodeoxyglucose (FDG) for initial staging and …

Background: Sarcomas represent a significant diagnostic and therapeutic challenge that
requires techniques to provide better assessment of the disease than provided by traditional …

Sarcomas—like leukemias, which are also mesodermal malignancies—carry biological
significance disproportionate to their clinical frequency. Identification of mutations and …

PET using 18F-FDG is increasingly used for the diagnosis and grading of tumors. Several
studies have been performed that evaluate the diagnostic and grading performance of 18F …

[18 F]-2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) is considered a
valuable tool in the diagnosis and staging of cancer. In addition, it seems promising as a …

Objective The purpose of these guidelines is to offer to the nuclear medicine team a
framework that could prove helpful in daily practice. These guidelines contain information …

The purpose of this study was to evaluate 18F-FDG PET studies of primary and recurrent
sarcomas for diagnosis and correlation with grading. Methods: The evaluation included 56 …